Clinical Trials Browser

Neoplasm Metastasis × dostarlimab × Clear all

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05201547 2025-12-04

DOMENICA

Phase 3 Active not recruiting

260 enrolled

Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT06333314 2025-12-02

Pan-MSI-ACSE

Phase 2 Recruiting

120 enrolled

EndocrineSarcoma

Neoplasm Metastasis, Neoplasms, Sarcoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine

NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1 Completed

60 enrolled 91 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

3,000 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Clinical Trials

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

DOMENICA

Pan-MSI-ACSE

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

IMPRESS-N

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma